Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC

BACKGROUND: Toripalimab shows antitumor efficacy in cholangiocarcinoma. Radiotherapy (RT) may enhance systemic responses of PD-1 inhibitors and lenvatinib. This study was designed to assess the safety and feasibility of toripalimab plus lenvatinib with or without RT in advanced BTC. METHODS: This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yunchao, Zhang, Nan, Xue, Jingnan, Zhu, Chengpei, Wang, Yanyu, Zhang, Longhao, Yang, Xu, Wang, Hao, Wang, Shanshan, Chao, Jiashuo, Yang, Xiaobo, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887048/
https://www.ncbi.nlm.nih.gov/pubmed/36733485
http://dx.doi.org/10.3389/fimmu.2023.1084843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887048/
https://www.ncbi.nlm.nih.gov/pubmed/36733485
http://dx.doi.org/10.3389/fimmu.2023.1084843

Ejemplares similares